Definition

A preparation of human autologous T lymphocytes that are genetically modified to express a T-cell receptor (TCR) specific for the human cancer-testis antigen NY-ESO-1 and the CD8alpha co-receptor, with potential immunostimulating and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-NY-ESO-1 TCR/CD8alpha-expressing T cells GSK3901961 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T cells into CD8+ cytotoxic T cells.